Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Gut
    September 2022
  1. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    >> Share

  2. BYRNE CD, Targher G
    Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Gut. 2022;71:1695-1696.
    >> Share

  3. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    >> Share

    August 2022

  4. Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2022;71:e9.
    >> Share

  5. LIU N, Wang X, Steer CJ, Song G, et al
    MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells.
    Gut. 2022;71:1642-1655.
    >> Share

  6. ZHOU L, Yu KH, Wong TL, Zhang Z, et al
    Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.
    Gut. 2022;71:1656-1668.
    >> Share

  7. REVIA S, Seretny A, Wendler L, Banito A, et al
    Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Gut. 2022;71:1613-1628.
    >> Share

  8. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    >> Share

    July 2022
  9. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    >> Share

  10. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    >> Share

  11. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    >> Share

  12. GRACIA-SANCHO J, Dufour JF
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.
    >> Share

  13. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    >> Share

  14. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    >> Share

    June 2022
  15. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    >> Share

  16. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.
    >> Share

  17. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    >> Share

  18. MITHIEUX G
    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.
    >> Share

  19. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
    Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
    Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
    >> Share

  20. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    >> Share

    May 2022
  21. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    >> Share

  22. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
    British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
    Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
    >> Share

  23. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    >> Share

  24. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
    Hepatic p63 regulates glucose metabolism by repressing SIRT1.
    Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
    >> Share

  25. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
    >> Share

  26. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    >> Share

  27. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
    Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Gut. 2022;71:983-990.
    >> Share

    April 2022
  28. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
    >> Share

  29. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    >> Share

  30. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.
    >> Share

  31. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    >> Share

  32. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    >> Share

    March 2022
  33. ZHANG C, Li J, Cheng Y, Meng F, et al
    Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
    Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
    >> Share

  34. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    >> Share

  35. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    >> Share

  36. RHA MS, Han JW, Koh JY, Lee HS, et al
    Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
    Gut. 2022;71:605-615.
    >> Share

    February 2022
  37. LU LG, Zhou ZL, Wang XY, Liu BY, et al
    PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
    >> Share

  38. SUN S, Yang Q, Zhou Q, Cao W, et al
    Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
    Gut. 2022;71:443-445.
    >> Share

  39. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    >> Share

  40. FRANCQUE S, Wong VW
    NAFLD in lean individuals: not a benign disease.
    Gut. 2022;71:234-236.
    >> Share

  41. YOUNES R, Govaere O, Petta S, Miele L, et al
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Gut. 2022;71:382-390.
    >> Share

  42. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
    Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
    Gut. 2022;71:402-414.
    >> Share

    January 2022
  43. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
    CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
    >> Share

  44. JI F, Zhang J, Liu N, Gu Y, et al
    Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
    Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
    >> Share

  45. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    >> Share

  46. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
    Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
    Gut. 2022;71:148-155.
    >> Share

  47. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Gut. 2022;71:156-162.
    >> Share

    December 2021
  48. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
    Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
    >> Share

  49. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    >> Share

  50. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    >> Share

  51. BANG JY, Ward TJ, Guirguis S, Krall K, et al
    Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
    Gut. 2021;70:2224-2226.
    >> Share

  52. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
    Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
    Gut. 2021;70:2283-2296.
    >> Share

  53. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    >> Share

  54. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
    Uphill or downhill bleeding?
    Gut. 2021;70:2282-2348.
    >> Share

    November 2021
  55. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
    >> Share

    October 2021
  56. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    >> Share


  57. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.
    >> Share

  58. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    >> Share

  59. LIU T, Tan J, Wu M, Fan W, et al
    High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
    Gut. 2021;70:1965-1977.
    >> Share

  60. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    >> Share

  61. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
    Diet-refractory NASH in an elderly woman.
    Gut. 2021;70:1924-1945.
    >> Share

    September 2021
  62. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
    >> Share

  63. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
    Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Gut. 2021;70:1758-1767.
    >> Share

    August 2021
  64. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    >> Share

  65. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    >> Share

  66. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    >> Share

    July 2021
  67. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    >> Share

  68. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    >> Share

  69. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
    Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    Gut. 2021;70:1299-1308.
    >> Share

    June 2021
  70. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    >> Share

  71. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
    >> Share

    May 2021
  72. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    >> Share

  73. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    >> Share

  74. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021;70:962-969.
    >> Share

    April 2021
  75. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    >> Share

  76. YADAV DK, Singh A, Zhang Q, Bai X, et al
    Involvement of liver in COVID-19: systematic review and meta-analysis.
    Gut. 2021;70:807-809.
    >> Share

  77. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    >> Share

  78. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    >> Share

    March 2021
  79. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.
    >> Share

  80. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.
    >> Share

  81. SAPENA V, Enea M, Torres F, Celsa C, et al
    Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
    Gut. 2021 Mar 19. pii: gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663.
    >> Share

  82. ZHAN K, Liao S, Li J, Bai Y, et al
    Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation.
    Gut. 2021;70:628-629.
    >> Share

  83. KIM DH, Hong SB, Choi SH, Kim SY, et al
    Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323615. doi: 10.1136/gutjnl-2020-323615.
    >> Share

  84. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    >> Share

    February 2021
  85. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    >> Share

  86. CHEN HN, Shu Y, Liao F, Liao X, et al
    Genomic evolution and diverse models of systemic metastases in colorectal cancer.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
    >> Share

  87. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    >> Share

  88. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.
    >> Share

  89. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    >> Share

    January 2021
  90. YASKOLKA MEIR A, Rinott E, Tsaban G, Zelicha H, et al
    Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.
    Gut. 2021 Jan 18. pii: gutjnl-2020-323106. doi: 10.1136/gutjnl-2020-323106.
    >> Share

  91. AOKI S, Inoue K, Klein S, Halvorsen S, et al
    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
    Gut. 2021 Jan 11. pii: gutjnl-2020-322493. doi: 10.1136/gutjnl-2020-322493.
    >> Share

  92. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.
    >> Share

  93. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    >> Share

  94. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    >> Share

  95. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    >> Share

    December 2020
  96. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    >> Share

  97. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    >> Share

  98. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    >> Share

    November 2020
  99. SUN N, Shen C, Zhang L, Wu X, et al
    Hepatic Kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance.
    Gut. 2020 Nov 30. pii: gutjnl-2020-321774. doi: 10.1136/gutjnl-2020-321774.
    >> Share

  100. CALDERARO J, Kather JN
    Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322880. doi: 10.1136/gutjnl-2020-322880.
    >> Share

  101. KOH EH, Yoon JE, Ko MS, Leem J, et al
    Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
    Gut. 2020 Nov 18. pii: gutjnl-2020-322509. doi: 10.1136/gutjnl-2020-322509.
    >> Share

  102. HAO L, Zhong W, Dong H, Guo W, et al
    ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.
    Gut. 2020 Nov 11. pii: gutjnl-2020-321548. doi: 10.1136/gutjnl-2020-321548.
    >> Share

  103. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    >> Share

  104. CUBERO FJ
    Keeping the liver fit with TREM2 during hepatic carcinogenesis.
    Gut. 2020 Nov 4. pii: gutjnl-2020-322638. doi: 10.1136/gutjnl-2020-322638.
    >> Share

  105. SHANG R, Song X, Wang P, Zhou Y, et al
    Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Gut. 2020 Nov 3. pii: gutjnl-2020-320716. doi: 10.1136/gutjnl-2020-320716.
    >> Share

  106. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.
    >> Share

    October 2020
  107. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    >> Share

  108. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.
    >> Share

  109. TILG H, Targher G
    NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought.
    Gut. 2020 Oct 19. pii: gutjnl-2020-323188. doi: 10.1136/gutjnl-2020-323188.
    >> Share

  110. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    >> Share

  111. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    >> Share

  112. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.
    >> Share

  113. ZHANG N, Jiang W, Zhang Y, Song TQ, et al
    Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria.
    Gut. 2020;69:1893-1895.
    >> Share

  114. DE TONI EN
    Immune checkpoint inhibitors: use them early, combined and instead of TACE?
    Gut. 2020;69:1887-1888.
    >> Share

  115. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    >> Share

  116. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    >> Share

    September 2020
  117. SHI JY, Wang X, Ding GY, Dong Z, et al
    Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.
    Gut. 2020 Sep 30. pii: gutjnl-2020-320930. doi: 10.1136/gutjnl-2020-320930.
    >> Share

  118. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    >> Share

  119. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    >> Share

  120. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.
    >> Share

  121. VON FELDEN J, Garcia-Lezana T, Schulze K, Losic B, et al
    Liquid biopsy in the clinical management of hepatocellular carcinoma.
    Gut. 2020 Sep 3. pii: gutjnl-2019-320282. doi: 10.1136/gutjnl-2019-320282.
    >> Share

  122. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    >> Share

  123. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.
    >> Share

    August 2020
  124. SHARMA S, Elhence A, Vaishnav M, Kumar R, et al
    COVID-19 in patients with cirrhosis: understanding adverse impact.
    Gut. 2020 Aug 21. pii: gutjnl-2020-322561. doi: 10.1136/gutjnl-2020-322561.
    >> Share

  125. YAMAMOTO A, Kawada N, Jogo A, Murai K, et al
    Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322367. doi: 10.1136/gutjnl-2020-322367.
    >> Share

  126. YANG H, Sun L, Mao Y
    Response letter to: letter to the editor: three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Aug 14. pii: gutjnl-2020-322471. doi: 10.1136/gutjnl-2020-322471.
    >> Share

  127. PINTER M, Scheiner B, Peck-Radosavljevic M
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Gut. 2020 Aug 3. pii: gutjnl-2020-321702. doi: 10.1136/gutjnl-2020-321702.
    >> Share

  128. BOLLIPO S, Kapuria D, Rabiee A, Ben-Yakov G, et al
    One world, one pandemic, many guidelines: management of liver diseases during COVID-19.
    Gut. 2020;69:1369-1372.
    >> Share

  129. TARGHER G, Mantovani A, Byrne CD, Wang XB, et al
    Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
    Gut. 2020;69:1545-1547.
    >> Share

  130. RADU P, Dufour JF
    Changing TACTICS in intermediate HCC: TACE plus sorafenib.
    Gut. 2020;69:1374-1376.
    >> Share

  131. TILG H, Burcelin R, Tremaroli V
    Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?
    Gut. 2020;69:1373-1374.
    >> Share

  132. JOHNSTON M, Cook C, Buchanan RM
    RE: Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2020;69:1536-1537.
    >> Share

    July 2020
  133. KAUR S, Tripathi DM, Ghosh S
    Three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Jul 21. pii: gutjnl-2020-322317. doi: 10.1136/gutjnl-2020-322317.
    >> Share

  134. BAJAJ JS, Garcia-Tsao G, Biggins S, Kamath PS, et al
    Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
    Gut. 2020 Jul 13. pii: gutjnl-2020-322118. doi: 10.1136/gutjnl-2020-322118.
    >> Share

  135. WEBER S, Mayerle J, Irlbeck M, Gerbes AL, et al
    Severe liver failure during SARS-CoV-2 infection.
    Gut. 2020;69:1365-1367.
    >> Share

  136. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.
    >> Share

    June 2020
  137. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.
    >> Share

  138. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    >> Share

  139. STENGEL S, Steube A, Kose-Vogel N, Kirchberger-Tolstik T, et al
    Primed circulating monocytes are a source of IL-1beta in patients with cirrhosis and ascites.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321597. doi: 10.1136/gutjnl-2020-321597.
    >> Share

  140. BECCHETTI C, Zambelli MF, Pasulo L, Donato MF, et al
    COVID-19 in an international European liver transplant recipient cohort.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321923. doi: 10.1136/gutjnl-2020-321923.
    >> Share

  141. BREITKOPF-HEINLEIN K, Syn WK
    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.
    >> Share

  142. BAYARD Q, Nault JC, Zucman-Rossi J
    RSPO2 abnormal transcripts result from read-through in liver tumours with high ss-catenin activation and CTNNB1 mutations.
    Gut. 2020;69:1152-1153.
    >> Share

  143. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    >> Share

  144. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    >> Share

    May 2020
  145. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    >> Share

  146. YANG H, Sun L, Pang Y, Hu D, et al
    Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure.
    Gut. 2020 May 20. pii: gutjnl-2019-319960. doi: 10.1136/gutjnl-2019-319960.
    >> Share

  147. NATHANI P, Gopal P, Rich N, Yopp A, et al
    Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis.
    Gut. 2020 May 12. pii: gutjnl-2020-321040. doi: 10.1136/gutjnl-2020-321040.
    >> Share

  148. DUFOUR JF, Caussy C, Loomba R
    Combination for therapy non-alcoholic steatohepatitis: rationale, opportunities and challenges.
    Gut. 2020 May 7. pii: gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.
    >> Share

    April 2020
  149. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.
    >> Share

  150. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    >> Share

  151. CINNAMON E, Pikarsky E
    Are we ready for targeted therapy combinations in HCC?
    Gut. 2020;69:613-614.
    >> Share

  152. AVILA MA, Dufour JF, Gerbes AL, Zoulim F, et al
    Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.
    Gut. 2020;69:764-780.
    >> Share

  153. LA BELLA T, Imbeaud S, Peneau C, Mami I, et al
    Adeno-associated virus in the liver: natural history and consequences in tumour development.
    Gut. 2020;69:737-747.
    >> Share

  154. NATHWANI R, Mullish BH, Kockerling D, Rajani N, et al
    Recurrent bacteraemia following variceal haemorrhage.
    Gut. 2020;69:726-780.
    >> Share

    March 2020
  155. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    >> Share

  156. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    >> Share

  157. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    >> Share

  158. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    >> Share

    February 2020
  159. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    >> Share

    January 2020
  160. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    >> Share

    December 2019
  161. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016